|
|
|
| Correlation between Dialysis Methods and Quality of Life Efficacy and Microinflammation Indicators in Maintaining Dialysis Patients |
| MA Bing, YAN Miaoting, MA Li, et al |
| The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Urumqi 830000, China |
|
|
|
|
Abstract Objective: To explore the correlation of quality of life, dialysis mode, efficacy and microinflammation index in maintaining dialysis patients. Methods: From January 2018 to January 2019, 90 patients with end-stage renal disease who underwent dialysis in our hospital were randomly divided into three groups: A, B and C. Each group consisted of 30 patients. They were treated with hemodiafiltration (HDF), high-flux hemodialysis (HFHD) and high-flux hemodialysis combined with hemoperfusion (HFHD+HP). 6 months after treatment, the clinical efficacy, microinflammation index, quality of life and complications of the three groups were compared before and after treatment. Results: After 6 months of treatment, ALB and Kt/V in the three groups were significantly higher than those before treatment (P<0.05), and increased from group A to group C in turn (P<0.0125), BUN, Scr, β2-MG, PTH, CRP,IL-10,Hcy and TNF-a levels were significantly lower than those before treatment (P<0.05), and decreased from group A to group C in turn (P<0.0125) ; There was statistical difference in the incidence of complications after treatment among the three groups (P<0.05), and the incidence of complications in group A was higher than that in group C (30.00% vs. 3.33%, P<0.0125) ; After treatment, the SF-36 and KDTA scores in the three groups were significantly higher than those before treatment (P<0.05), and increased from group A to group C (P<0.0125). Conclusion: Compared with HDF and HFHD, dialysis with HFHD and HP in series can significantly improve the clinical efficacy, control the level of inflammation and improve the quality of life, and the safety is guaranteed.
|
|
|
|
|
|
[1] London GM. Arterial stiffness in chronic kidney disease and end-stage renal disease[J]. Blood Purif, 2018,45(13):154.
[2] Cozzolino M, Elli F, Carugo S, et al. Secondary hyperparathyroidism in end-stage renal disease: no longer a matter for surgeons[J]. Blood Purif, 2016,42(1):44.
[3] Zhao F, Wang Z, Liu L, et al. The influence of mortality rate from membrane flux for end-stage renal disease: a meta-analysis[J]. Nephrol Ther, 2016,13(1):9~13.
[4] Saad MM, Douaihy YE, Boumitri C, et al. Predictors of quality of life in patients with end-stage renal disease on hemodialysis[J]. International Journal of Nephrology & Renovascular Disease, 2015,8(12):119~123.
[5] Uri PS, Popovi J, Jankovi A, et al. Parameters of hemodialysis adequacy and patients survival depending on treatment modalitis[J]. Med Pregl, 2015,68(8):251~253.
[6] Seibert E, Zohles K, Ulrich C, et al. Association between autonomic nervous dysfunction and cellular inflammation in end-stage renal disease[J]. BMC Cardiovasc Disord, 2016,16(1):210~213.
[7] Fadel F, Bazraa HM, Abdelrahman SM, et al. Visfatin versus flow-mediated dilatation as a marker of endothelial dysfunction in pediatric renal transplant recipients[J]. Open Access Maced Med Sci, 2017,5(2):222~227.
[8] Derosa G, Libetta C, Esposito P, et al. Effects of two different dialytic treatments on inflammatory markers in people with end-stage renal disease with and without type 2 diabetes mellitus[J]. Cytokine, 2017,92(10):75~79.
[9] Tiranathanagul K, Susantitaphong P, Srisawat N, et al. Ten-year survival of end-stage renal disease patients treated with high-efficiency online hemodiafiltration: a cohort study of a center in south east asia[J]. Nephron, 2018,139(2):1234~1239. |
|
|
|
2020, Vol. 26 
